287 related articles for article (PubMed ID: 27992544)
21. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
[TBL] [Abstract][Full Text] [Related]
22. Highly Drug-Resistant HIV-1 Protease Mutant PRS17 Shows Enhanced Binding to Substrate Analogues.
Agniswamy J; Kneller DW; Brothers R; Wang YF; Harrison RW; Weber IT
ACS Omega; 2019 May; 4(5):8707-8719. PubMed ID: 31172041
[TBL] [Abstract][Full Text] [Related]
23. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
[TBL] [Abstract][Full Text] [Related]
24. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
25. Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.
Henes M; Kosovrasti K; Lockbaum GJ; Leidner F; Nachum GS; Nalivaika EA; Bolon DNA; Kurt Yilmaz N; Schiffer CA; Whitfield TW
Biochemistry; 2019 Sep; 58(35):3711-3726. PubMed ID: 31386353
[TBL] [Abstract][Full Text] [Related]
26. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
Liu F; Boross PI; Wang YF; Tozser J; Louis JM; Harrison RW; Weber IT
J Mol Biol; 2005 Dec; 354(4):789-800. PubMed ID: 16277992
[TBL] [Abstract][Full Text] [Related]
27. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
Wang YF; Tie Y; Boross PI; Tozser J; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2007 Sep; 50(18):4509-15. PubMed ID: 17696515
[TBL] [Abstract][Full Text] [Related]
28. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.
Sayer JM; Liu F; Ishima R; Weber IT; Louis JM
J Biol Chem; 2008 May; 283(19):13459-70. PubMed ID: 18281688
[TBL] [Abstract][Full Text] [Related]
29. Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site.
Sadiq SK; Wan S; Coveney PV
Biochemistry; 2007 Dec; 46(51):14865-77. PubMed ID: 18052195
[TBL] [Abstract][Full Text] [Related]
30. Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.
Clemente JC; Moose RE; Hemrajani R; Whitford LR; Govindasamy L; Reutzel R; McKenna R; Agbandje-McKenna M; Goodenow MM; Dunn BM
Biochemistry; 2004 Sep; 43(38):12141-51. PubMed ID: 15379553
[TBL] [Abstract][Full Text] [Related]
31. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.
Kovalevsky AY; Liu F; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
J Mol Biol; 2006 Oct; 363(1):161-73. PubMed ID: 16962136
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.
Liu F; Kovalevsky AY; Louis JM; Boross PI; Wang YF; Harrison RW; Weber IT
J Mol Biol; 2006 May; 358(5):1191-9. PubMed ID: 16569415
[TBL] [Abstract][Full Text] [Related]
33. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
Kovalevsky AY; Tie Y; Liu F; Boross PI; Wang YF; Leshchenko S; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2006 Feb; 49(4):1379-87. PubMed ID: 16480273
[TBL] [Abstract][Full Text] [Related]
35. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
36. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
Mahalingam B; Louis JM; Hung J; Harrison RW; Weber IT
Proteins; 2001 Jun; 43(4):455-64. PubMed ID: 11340661
[TBL] [Abstract][Full Text] [Related]
37. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
38. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Eche S; Kumar A; Sonela N; Gordon ML
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805099
[TBL] [Abstract][Full Text] [Related]
39. Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR
Agniswamy J; Kneller DW; Ghosh AK; Weber IT
Biochem Biophys Res Commun; 2021 Aug; 566():30-35. PubMed ID: 34111669
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]